China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts

Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursda

HK24H 僅展示標題與短摘要，全文版權歸 SCMP Business 所有。